#NewMember | "AseBio will enable us to provide differential and disruptive value"

AseBio. What does your company's work bring to the table and what is its strength?

Juan Basterra. At Mikrobiomik we aspire to be the first company in the world to market in the EU the first biological medicine based on intestinal microbiota in the indication of recurrence of intestinal infection by Clostridioides difficile in an innovative capsule format and in a simple dosage of 4 capsules in a single dose. We are currently conducting a phase III clinical trial in 21 hospitals in Spain with our leading product MBK-01 (full spectrum microbiota) with the aim of demonstrating superiority, both in terms of safety and efficacy, over the antibiotic fidaxomicin.

AseBio. What is AseBio for you?

Juan Basterra. Mikrobiomik is in an active partnership search phase, as our objective is to research, develop and produce microbiota-based medicines, leaving commercialisation to third parties through licensing agreements.

AseBio. When did you first hear about AseBio?

Juan Basterra. Although we have known Asebio practically since its foundation, Mikrobiomik is a biopharmaceutical company only 3 years old and we have decided to become partners with the certainty that, from the perspective of the microbiome, we can provide differential and disruptive value compared to the traditional pharmaceutical world.

AseBio. What do you expect from being part of an association like AseBio?

Juan Basterra. We have already joined, with great enthusiasm, the different working groups of Asebio, with special interest in the working group on antibiotic resistance where the field of microbiota has a lot to contribute and to say.

AseBio.What is the biggest challenge facing the biotech sector (or your company)?

Juan Basterra. Although it may sound cliché, our greatest challenge is to save lives by leading the research, development and production of biological medicines based on the human microbiome.